AI Article Synopsis
- Low uptake and adherence to breast cancer preventive therapy are primarily due to fears of serious side effects and menopausal symptoms.
- A study indicates that low-dose tamoxifen is effective and has fewer side effects for high-risk women, leading to better patient adherence.
- More than 70% of women who were counseled about low-dose tamoxifen continued taking it after one year, suggesting this treatment could improve breast cancer prevention efforts and lower related mortality rates.
Article Abstract
The uptake and adherence of preventive therapy of breast cancer in clinical practice are low because of fear of serious adverse events and menopausal symptoms. Low-dose tamoxifen has been shown to retain efficacy while reducing toxicity in high-risk women. In this issue of the journal, Cornell and colleagues evaluated uptake, adherence, and tolerability of low-dose tamoxifen in high-risk women. More than 70% of patients reported that they took low-dose tamoxifen after counseling and were still taking the medication at 1 year. This paradigm shift may move the field of breast cancer prevention forward and reduce breast cancer incidence and mortality. See related article by Cornell et al., p. 565.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1158/1940-6207.CAPR-24-0483 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!